Found: 395
Select item for more details and to access through your institution.
Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience.
- Published in:
- Clinical & Experimental Dermatology, 2024, v. 49, n. 9, p. 1002, doi. 10.1093/ced/llae067
- By:
- Publication type:
- Article
Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study.
- Published in:
- Allergy, 2024, v. 79, n. 9, p. 2448, doi. 10.1111/all.16256
- By:
- Publication type:
- Article
Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review.
- Published in:
- Journal of Clinical Medicine, 2024, v. 13, n. 16, p. 4844, doi. 10.3390/jcm13164844
- By:
- Publication type:
- Article
What can be learned from real-world data about chronic spontaneous urticaria?
- Published in:
- Allergy & Asthma Proceedings, 2024, v. 45, n. 4, p. 255, doi. 10.2500/aap.2024.45.240041
- By:
- Publication type:
- Article
Total IgE as a biomarker of omalizumab response in chronic spontaneous urticaria: A meta-analysis.
- Published in:
- Allergy & Asthma Proceedings, 2024, v. 45, n. 2, p. 97, doi. 10.2500/aap.2024.45.230092
- By:
- Publication type:
- Article
Current and future management of chronic spontaneous urticaria and chronic inducible urticaria.
- Published in:
- Allergy & Asthma Proceedings, 2023, v. 44, n. 1, p. 3, doi. 10.2500/aap.2023.44.220093
- By:
- Publication type:
- Article
Predictive factors of recurrence after omalizumab cessation in the elderly with urticaria: A real-life study.
- Published in:
- Allergy & Asthma Proceedings, 2022, v. 43, n. 6, p. 519, doi. 10.2500/aap.2022.43.220068
- By:
- Publication type:
- Article
Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study.
- Published in:
- Allergy & Asthma Proceedings, 2021, v. 42, n. 3, p. 235, doi. 10.2500/aap.2021.42.210014
- By:
- Publication type:
- Article
Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations.
- Published in:
- Allergy & Asthma Proceedings, 2021, v. 42, n. 1, p. 65, doi. 10.2500/aap.2021.42.200101
- By:
- Publication type:
- Article
Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
- Published in:
- Allergy & Asthma Proceedings, 2021, v. 42, n. 1, p. e17, doi. 10.2500/aap.2021.42.200088
- By:
- Publication type:
- Article
Biomarcadores na Urticária Crónica Espontânea.
- Published in:
- Revista da Sociedade Portuguesa de Dermatologia e Venereologia, 2021, v. 79, n. 2, p. 147, doi. 10.29021/spdv.79.2.1394
- By:
- Publication type:
- Article
COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)—a Randomized Controlled Clinical Trial.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 4, p. 1, doi. 10.1093/ofid/ofae102
- By:
- Publication type:
- Article
Influence of Staphylococcal enterotoxin‐specific IgE sensitization on therapeutic efficacy of omalizumab therapy in severe asthma.
- Published in:
- Respirology, 2024, v. 29, n. 3, p. 252, doi. 10.1111/resp.14663
- By:
- Publication type:
- Article
Severe asthma ILC2s demonstrate enhanced proliferation that is modified by biologics.
- Published in:
- Respirology, 2023, v. 28, n. 8, p. 758, doi. 10.1111/resp.14506
- By:
- Publication type:
- Article
P9‐33: A study of severe asthma patients who continued omalizumab treatment for more than 3 years.
- Published in:
- Respirology, 2021, v. 26, p. 375, doi. 10.1111/resp.14150_734
- Publication type:
- Article
P9‐28: A comparison of clinical characteristics, between severe asthmatics who continued omalizumab administration and those underwent switch to other biologic agents.
- Published in:
- Respirology, 2021, v. 26, p. 373, doi. 10.1111/resp.14150_729
- Publication type:
- Article
P9‐33: A study of severe asthma patients who continued omalizumab treatment for more than 3 years.
- Published in:
- Respirology, 2021, v. 26, p. 375, doi. 10.1111/resp.14150_734
- Publication type:
- Article
P9‐28: A comparison of clinical characteristics, between severe asthmatics who continued omalizumab administration and those underwent switch to other biologic agents.
- Published in:
- Respirology, 2021, v. 26, p. 373, doi. 10.1111/resp.14150_729
- Publication type:
- Article
Unravelling the effects of omalizumab on fibrocytes.
- Published in:
- Respirology, 2021, v. 26, n. 9, p. 825, doi. 10.1111/resp.14115
- By:
- Publication type:
- Article
Omalizumab in combination with subcutaneous immunotherapy for the treatment of multiple allergies associated with attention-deficit/hyperactivity disorder: a case report and a literature review.
- Published in:
- Frontiers in Pharmacology, 2024, p. 01, doi. 10.3389/fphar.2024.1367551
- By:
- Publication type:
- Article
Prevention of omalizumab for seasonal allergic rhinoconjunctivitis: a retrospective cohort study.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.913424
- By:
- Publication type:
- Article
Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.928621
- By:
- Publication type:
- Article
The Potential Role of Basophils in Urticaria.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.883692
- By:
- Publication type:
- Article
Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.874108
- By:
- Publication type:
- Article
Case Report: Safety and Efficacy of Omalizumab in a 13-Year-Old Patient With Chronic Spontaneous Urticaria and Type 1 Diabetes.
- Published in:
- Frontiers in Immunology, 2022, v. 13, p. 1, doi. 10.3389/fimmu.2022.853561
- By:
- Publication type:
- Article
A long‐term course of alopecia areata during omalizumab treatment: a case report.
- Published in:
- International Journal of Dermatology, 2023, v. 62, n. 12, p. e621, doi. 10.1111/ijd.16823
- By:
- Publication type:
- Article
Efficacy and safety of biological agents for pemphigoid: a systematic review and meta‐analysis.
- Published in:
- International Journal of Dermatology, 2023, v. 62, n. 8, p. 1000, doi. 10.1111/ijd.16678
- By:
- Publication type:
- Article
Cold urticarial vasculitis successfully treated with omalizumab.
- Published in:
- International Journal of Dermatology, 2023, v. 62, n. 2, p. e77, doi. 10.1111/ijd.16133
- By:
- Publication type:
- Article
Concurrent use of omalizumab and dupilumab in a 47‐year‐old woman with chronic spontaneous urticaria and atopic dermatitis.
- Published in:
- International Journal of Dermatology, 2022, v. 61, n. 5, p. e173, doi. 10.1111/ijd.16009
- By:
- Publication type:
- Article
COVID‐19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.
- Published in:
- International Journal of Dermatology, 2021, v. 60, n. 2, p. 253, doi. 10.1111/ijd.15379
- By:
- Publication type:
- Article
IFN‐γ/IL‐6 and related cytokines in chronic spontaneous urticaria: evaluation of their pathogenetic role and changes during omalizumab therapy.
- Published in:
- International Journal of Dermatology, 2020, v. 59, n. 5, p. 590, doi. 10.1111/ijd.14812
- By:
- Publication type:
- Article
A Real-World Analysis of Relapse Rate and Efficacy of a Restricted Monthly Dose of Omalizumab in Recalcitrant Chronic Spontaneous Urticaria in India.
- Published in:
- Indian Dermatology Online Journal, 2020, v. 11, n. 5, p. 835, doi. 10.4103/idoj.IDOJ_499_19
- By:
- Publication type:
- Article
Complete remission in a patient with treatment refractory bullous pemphigoid after a single dose of omalizumab.
- Published in:
- Indian Dermatology Online Journal, 2020, v. 11, n. 4, p. 607, doi. 10.4103/idoj.IDOJ_438_19
- By:
- Publication type:
- Article
Real-World Observational Study on the Characteristics and Treatment Patterns of Allergic Asthma Patients Receiving Omalizumab in Canada.
- Published in:
- Patient Preference & Adherence, 2020, v. 14, p. 725, doi. 10.2147/PPA.S248324
- By:
- Publication type:
- Article
Lung function trajectories in a cohort of patients with moderate‐to‐severe asthma on mepolizumab, omalizumab, or dupilumab.
- Published in:
- Allergy, 2024, v. 79, n. 5, p. 1195, doi. 10.1111/all.16002
- By:
- Publication type:
- Article
A randomized, double‐blind placebo‐controlled study on the efficacy of Omalizumab on food allergy threshold in children with severe food allergy.
- Published in:
- Allergy, 2024, v. 79, n. 4, p. 964, doi. 10.1111/all.16046
- By:
- Publication type:
- Article
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients.
- Published in:
- Allergy, 2024, v. 79, n. 2, p. 384, doi. 10.1111/all.15867
- By:
- Publication type:
- Article
IgE glycosylation is essential for the function of omalizumab.
- Published in:
- Allergy, 2023, v. 78, n. 9, p. 2546, doi. 10.1111/all.15748
- By:
- Publication type:
- Article
Ligelizumab impairs IgE‐binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN‐α production and FOXP3<sup>+</sup> Treg generation.
- Published in:
- Allergy, 2023, v. 78, n. 4, p. 1060, doi. 10.1111/all.15567
- By:
- Publication type:
- Article
The impact of maternal‐fetal omalizumab transfer on peanut‐specific responses in an ex vivo placental perfusion model.
- Published in:
- Allergy, 2022, v. 77, n. 12, p. 3684, doi. 10.1111/all.15468
- By:
- Publication type:
- Article
Metabolomics to identify omalizumab responders among children with severe asthma: A prospective study.
- Published in:
- Allergy, 2022, v. 77, n. 9, p. 2852, doi. 10.1111/all.15385
- By:
- Publication type:
- Article
Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one‐year extension study.
- Published in:
- Allergy, 2022, v. 77, n. 7, p. 2175, doi. 10.1111/all.15175
- By:
- Publication type:
- Article
Phase 2, randomized multi oral immunotherapy with omalizumab 'real life' study.
- Published in:
- Allergy, 2022, v. 77, n. 6, p. 1873, doi. 10.1111/all.15217
- By:
- Publication type:
- Article
EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old.
- Published in:
- Allergy, 2022, v. 77, n. 1, p. 17, doi. 10.1111/all.15030
- By:
- Publication type:
- Article
Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database.
- Published in:
- Allergy, 2021, v. 76, n. 10, p. 3209, doi. 10.1111/all.15008
- By:
- Publication type:
- Article
Predictors of treatment response in chronic spontaneous urticaria.
- Published in:
- Allergy, 2021, v. 76, n. 10, p. 2965, doi. 10.1111/all.14757
- By:
- Publication type:
- Article
Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab.
- Published in:
- Allergy, 2021, v. 76, n. 9, p. 2809, doi. 10.1111/all.14833
- By:
- Publication type:
- Article
Real‐life study in non‐atopic severe asthma patients achieving disease control by omalizumab treatment.
- Published in:
- Allergy, 2021, v. 76, n. 6, p. 1868, doi. 10.1111/all.14668
- By:
- Publication type:
- Article
Extracellular vesicle microRNAs as predictors of response to omalizumab in chronic spontaneous urticaria.
- Published in:
- Allergy, 2021, v. 76, n. 4, p. 1274, doi. 10.1111/all.14702
- By:
- Publication type:
- Article
Omalizumab in children and adolescents with chronic urticaria: A 16‐week real‐world study.
- Published in:
- Allergy, 2021, v. 76, n. 4, p. 1271, doi. 10.1111/all.14686
- By:
- Publication type:
- Article